Abstract P4-02-13: Homologous recombination deficiency, RB-loss gene signatures, intrinsic subtype and response to neoadjuvant treatment in HR+/HER2- early breast cancer: a correlative analysis of two phase II trials
Gaia Griguolo(University of North Carolina at Chapel Hill), Maria Vittoria Dieci(Istituto Oncologico Veneto), Grazia Maria Vernaci(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Claudia Pinato(Istituto Oncologico Veneto), Francesca Schiavi(Istituto Oncologico Veneto), Giancarlo Bisagni, Tommaso Giarratano(Istituto Oncologico Veneto), Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Marcello Mele(University of Pisa), Antonio Frassoldati(University of Ferrara), Simon Spazzapan(Centro di Riferimento Oncologico), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Enrico Tagliafico(University of Modena and Reggio Emilia), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Federica Miglietta(University of Padua), Aleix Prat(Hospital Clínic de Barcelona), Daniele Generali(University of Trieste)
Cited by 2
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830